Samsung Biologics posted its strongest performance to date in the first half of 2025, with revenue surpassing $1.9 billion and operating profit nearing $700 million. Growth was fueled by the ramp-up of its fourth plant, the launch of its fifth, and a wave of large-scale manufacturing contracts with global pharmaceutical companies.

In January, the company secured a $1.8 billion deal with a European partner, followed in July by a $1.3 billion contract with a U.S. firm. For the second half, Samsung Biologics is preparing a corporate spin-off and new ventures in organoid-based businesses—moves expected to reshape its profit structure and long-term growth trajectory.

Samsung Biologics recorded consolidated revenue of $1.9 billion and operating profit of $692 million in the first half, up 23% and 47% year-on-year. On a standalone basis, revenue surpassed $1.44 billion for the first time since its founding.

Second-quarter results echoed the trend, with revenue of $727 million and operating profit of $343 million. Despite rising administrative expenses, the company maintained a robust operating margin of 47%.

CDMO services remained the growth engine, accounting for two-thirds of sales ($1.19 billion). Biosimilars generated $571 million, about 31% of revenue.

Order momentum has been strong, with contracts signed across regions. Beyond its headline $1.44 billion European deal in January and $1.3 billion U.S. contract in September, the company secured mid-sized agreements including $504 million with a U.S. partner in April and additional $144 million contracts in Europe and Asia in May. Deals in June and August further boosted year-to-date bookings to $3.74 billion.

While Europe and the U.S. dominate, Asian clients are steadily increasing, diversifying the customer portfolio.

Since opening its first 30,000-liter facility in 2012, Samsung Biologics has expanded capacity step by step, surpassing 300,000 liters with Plants 2 and 3. Plant 4, launched in 2023, added 240,000 liters, and Plant 5 in April 2025 brought total capacity to 784,000 liters.

Looking ahead, Plants 6 through 8 at the company’s second Songdo campus will raise capacity to 1.324 million liters by 2032, positioning Samsung Biologics to meet surging global demand.

On May 22, Samsung Biologics approved a simple spin-off to sharpen strategic focus. The current entity will remain a pure-play CDMO, while a new company—Samsung Epics Holdings—will oversee the biosimilar business, with Samsung Bioepis as a wholly owned subsidiary.

Originally planned for October, the restructuring was rescheduled to November 1 after an extended Korea Exchange review. The extraordinary shareholders’ meeting will be held on October 17, with relisting set for November 24. Samsung Bioepis CEO Kyung-ah Kim will also serve as CEO of Samsung Epics Holdings.

The split aims to eliminate conflicts of interest, enhance client partnerships, and allow independent decision-making. Post spin-off, Samsung Biologics will continue to pursue capacity expansion, service diversification, and global outreach, while Samsung Epics Holdings will focus on building a biosimilar pipeline of more than 20 products and advancing into new modalities.